Organogenesis is acquiring NuTech Medical, developer of amniotic products with application in soft tissue and bone regeneration.
NuTech Medical’s portfolio includes Affinity fresh amniotic allograft; NuShield dehydrated terminally-sterilized allograft and NuCel and ReNu cryopreserved allografts. NuTech Medical’s non-biologics product line will remain as a separate company, NuTech Spine.
NuTech Medical will continue existing operations as a division of Organogenesis, focused on surgical biologics. It will continue to develop and distribute products from existing facilities in Birmingham, Alabama, growing its present 150-rep sales network. NuTech’s President & CEO, Howard Walthall, will now preside over Organogenesis’ Surgical Division and also serve as Senior Vice President for Strategy and Development.
Organogenesis is acquiring NuTech Medical, developer of amniotic products with application in soft tissue and bone regeneration.
NuTech Medical's portfolio includes Affinity fresh amniotic allograft; NuShield dehydrated terminally-sterilized allograft and NuCel and ReNu cryopreserved allografts. NuTech Medical's non-biologics product...
Organogenesis is acquiring NuTech Medical, developer of amniotic products with application in soft tissue and bone regeneration.
NuTech Medical’s portfolio includes Affinity fresh amniotic allograft; NuShield dehydrated terminally-sterilized allograft and NuCel and ReNu cryopreserved allografts. NuTech Medical’s non-biologics product line will remain as a separate company, NuTech Spine.
NuTech Medical will continue existing operations as a division of Organogenesis, focused on surgical biologics. It will continue to develop and distribute products from existing facilities in Birmingham, Alabama, growing its present 150-rep sales network. NuTech’s President & CEO, Howard Walthall, will now preside over Organogenesis’ Surgical Division and also serve as Senior Vice President for Strategy and Development.
Copy to clipboard 
